• Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products.
• Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so
• Lexaria has been boosting its profile and revenue potential through licensing agreements with other companies
• Lexaria recently announced a licensing agreement with Cannadips CBD-maker The Boldt Runners Corporation
• The agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve the speed of its effectiveness and to combat the throat irritation that can accompany use of terpene-rich multi spectrum oils

Drug product consumption innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced a trade agreement that continues to advance the company’s revenue-building efforts through licensing its technology to other product manufacturers that can benefit from Lexaria’s DehydraTECH™ oral drug delivery IP.

The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO).

“This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine,” Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners Corporation (Cannadips), stated in a news release.

Lexaria has made its mission the development of swallowed drug substance consumption methods that approximate the rapid effectiveness of smoking or vaping, for example, while avoiding the dangers such drug inhalation can cause to users’ lungs. Those dangers gained new visibility during the past year as thousands of vape users fell seriously ill or died after inhaling products containing cannabis or nicotine deemed safer than tobacco smokes (http://ibn.fm/TlRbK).

The need for Lexaria’s IP has become evident as drug inhalation has become popular and has remained so despite science’s development of the means to demonstrate the dangers of smoked products, including cancers, on users’ lungs (http://ibn.fm/gVfND). Orally ingested medications and wellness products have in general been slower to act effectively on the user than inhaled substances and may ultimately enter the bloodstream in a more dilute measure than originally intended because of the body’s digestive screening mechanisms.

DehydraTECH has demonstrated its ability to speed its drug substance payloads to the bloodstream at rates much faster than un-enhanced oral ingestion. A new formulation of DehydraTECH has nearly doubled its rate of effectiveness, showing in lab testing that it can deliver cannabidiol (CBD) into the bloodstream at a rate 811 percent higher than generic industry control formulations, carrying 1,937 percent more CBD across the blood-brain barrier than generic industry control formulations (http://ibn.fm/wWvR4).

The body’s natural blood-brain barrier defense system protects our brain tissue from foreign substances, but also proves to be a deterrent for most small-molecule drugs that aim to enhance wellness through the central nervous system.

Cannadips’ American hemp-derived CBD pouches are an ideal product for pairing with DehydraTECH, offering 15 pouches with 10 mg of CBD (and no tobacco) each for oral delivery in tins similar in appearance to chewing tobacco. According to Lexaria’s news release, Cannadips uses terpene-rich multi spectrum oils as base ingredients that can cause some throat irritation. While some other products cut their terpenes to avoid the problem, DehydraTECH allows Cannadips to reduce the throat irritation while maintaining the entourage effect derived from multi-spectrum oils.

The Cannadips brand is being distributed nationally, including through Circle K convenience outlets, and are in about 5,000 stores in the United States with more in Europe.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Use of large-scale additive manufacturing has doubled in past year
• SGLB’s revolutionary quality-assurance software offers unique solution to industry’s most significant hurdles to mass production
• Sigma Labs set to reap lucrative benefits of revolutionary technology that enables 3D metal printing industry to scale production

A new study has revealed a significant increase in the use of large-scale additive manufacturing technology, also called 3D printing. Essentium, a Texas-based innovator in industrial additive-manufacturing platforms and filament materials, released the study and marks 2020 as the year when additive manufacturing at scale transforms manufacturing across a number of sectors, With multiple manufacturers across various sectors poised to embrace 3D printing at scale in 2020, Sigma Labs Inc. (NASDAQ: SGLB) aims to exploit this rapidly growing market opportunity with its revolutionary technology that enables in-process quality assurance of 3D-metal-printed parts. Sigma Labs is at the epicenter of the explosive additive manufacturing market growth as the leading provider of third-party in-process quality-assurance software for the commercial 3D metal printing industry.

With its unparalleled PrintRite3D® software that allows nondestructive quality assurance during the 3D printing of metal parts, Sigma Labs is ideally positioned to support the manufacturing sector in its mission to harness the transformative power of 3D printing in 2020 and beyond. PrintRite3D enables in-process quality control of 3D metal printing, allowing errors to be detected and corrected in real time, thus saving money and time while providing the ability to scale production. By providing the unique quality-assurance solution that the 3D metal printing industry needs in order to enter mainstream manufacturing, SGLB is set to capitalize on the tremendous growth in 3D printing applications across a wide variety of sectors, including aerospace, automotive, biomedical and electronics.

The Essentium study shows that the number of manufacturers using 3D printing for full-scale production has doubled since 2018 – from 21% in 2018 to 40% in 2019 (http://ibn.fm/U5zSE). Essentium surveyed 162 executives from manufacturing companies around the world about their perspectives on trends and challenges of 3D printing applications in manufacturing. The research revealed that although additive manufacturing has been limited by scale, as the technology and leading players are reaching a new level of maturity, a considerable growth in the use of large-scale additive manufacturing is found. The study shows that the number of manufacturers using 3D printing for full-scale production has doubled since 2018 – from 21% in 2018 to 40% in 2019.

The survey reports that the sharp rise in 3D printing adoption at scale is driven by manufacturers’ need to reduce lead times (61% of respondents) and manufacturing costs (58%). Additionally, 59% of respondents expect to benefit from mass customization, while 59% expect to expand speed-to-part production and 51% want to achieve high part performance. Despite this growing enthusiasm for 3D printing, many respondents still face obstacles such as high costs for 3D-printing materials (51%) and hardware (38%), as well as an inability to scale the current 3D printing technology (31%).

According to the study, open ecosystems are expected to be the prevailing format within the industry as technology hurdles surrounding scale, economics, strength and speed of production face away. With these problems mitigated, the future of the industry can allow for 3D printing users and vendors to realize greater control of their innovation, choice in materials, and industrial-scale production at lower costs.

With additive manufacturing at scale now becoming a reality, Sigma Labs constitutes a compelling investment opportunity as one of the primary enablers of 3D metal printing adoption for serial production.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• Hotel and vacation rental insurance gap coverer InsuraGuest is expanding its reach to Europe and Asia this year, and expects to be registered and licensed in all 50 states before the end of the year
• The company is currently licensed in 16 states from Maryland to Nevada, offering protection in case of accidental in-room damage, theft of personal property, accidental medical expense or accidental death and dismemberment during a stay at a property
• The lawsuit filed by Grammy Award-winning singer and actor Meat Loaf following his injury at a Texas hotel underscores the potential benefits of having stop-gap coverage in place
• 2020 kicked off with U.S. hotels reporting an increase in revenue per available room (RevPAR), average daily rate (ADR) and occupancy during the week of December 29 to January 4

A fall that Grammy Award-winning rock singer and actor Meat Loaf suffered last year and the resulting lawsuit against the Hyatt Regency Hotel in Texas (http://ibn.fm/HLiNH) serve as a high-profile example of the risks convenience service industries accept when they welcome guests, as well as the risks guests may face when they choose to stay at an establishment.

In the case of Meat Loaf, the 72-year-old entertainer was appearing at a convention when, according to the lawsuit and a video of the incident (http://ibn.fm/OdQXh), he suddenly fell from the stage, allegedly as a result of stepping off a section of the stage where a curtain he believed to be on the stage was instead hanging over a void.

Conscientious travelers who use the hotel industry and similar convenience services providers such as independent Airbnb-type properties and vacation rentals may carry traveler’s insurance but can find themselves facing crippling costs if a medical incident or unintended property damage during a property stay fall into a coverage gap.

Utah-based InsurTech (insurance + technology) innovator InsuraGuest Inc. is expanding its service reach nationwide and internationally to help prevent such coverage gaps. The company’s proprietary InsurTech software platform is being adopted by an increasing number of establishments. The company recently released its wholly owned subsidiary, InsuraGuest Insurance Agency, LLC (IG Agency). IG Agency brings licensed insurance sales in-house to increase InsuraGuest revenues and create shareholder value, and is currently available in 16 states, from Maryland to Nevada. InsuraGuest expects to have regulatory approval to sell in all states before the end of the year (http://ibn.fm/Fwtsb). The company is also entering European and Asian markets this year (http://ibn.fm/qMrVG).

“The InsuraGuest coverage is purchased by the property and provides coverage for covered claims from each registered guest and all room occupants upon check-in,” a company news release states (http://ibn.fm/eVCcd).

The InsurTech arena has blossomed during recent years, as tech startups have become a popular target for custom-tailored insurance coverage (http://ibn.fm/UDMnO). Within the travel stay industry, insurers are increasingly shifting toward filling the needs of small business startups operating as vacation rentals. Real estate analysts at iPropertyManagement.com predict the small vacation rental segment will become more profitable than hotels this year as the number of Airbnb users grows worldwide (http://ibn.fm/3jUZ0).

InsuraGuest Chairman and CEO Douglas Anderson noted that during 2018 travelers purchased 2.8 billion nightly hotel stays in Europe, compared with 1.1 billion in the United States.

“Additionally, $100 billion was spent on vacation rentals,” he stated (http://ibn.fm/V2YzA).

Although 2020 is barely under way, industry watchers are already expressing optimism for the year after reports noted that U.S hotels’ revenue per available room (RevPAR) rose 4 percent during the week of December 29 to January 4 while the average daily rate (ADR) and occupancy grew 4 percent and 0.3 percent, respectively (http://ibn.fm/rESoZ).

U.S. hotel occupancy was up 5.9 percent during the week before Christmas, according to the report.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to InsuraGuest are available in the company’s newsroom at http://ibn.fm/InsuraGuest

• In exclusive interview, CEO discusses how SRAX revolutionizes consumer data collection
• SRAX committed to building the most valuable opted-in data set in the world
• Company poised to capitalize on surge of multibillion-dollar data monetization market

In an exclusive interview at the LD Micro Main Event 2019, SRAX Inc. (NASDAQ: SRAX) Founder and CEO Christopher Miglino discussed how SRAX has revolutionized consumer data collection through BIGtoken, its proprietary, secure and transparent platform. The platform enables consumers to own and monetize their data as they earn rewards when they opt into the data sharing, as well as each time their data is purchased and each time they bring a new user to the platform.

With 16.4 million users worldwide, and three to five thousand new users joining each day, BIGtoken may be the most valuable opted-in data set in the world, said Miglino during the interview with SNN’s Robert Crafton (http://ibn.fm/LZQPh). Those numbers prove that consumers are looking for ways to receive compensation from marketers for using their data, said Miglino. Users worldwide can sign into the BIGtoken app, available for download on the App Store and Google Play, to see exactly how much they have earned.

The app benefits are mutual, Miglino pointed out, as consumers decide what data is shared, who can buy it and how it’s used, while advertisers gain verified consumer data for targeted marketing. Big brands such as Procter & Gamble and Kraft are purchasing BIGtoken data.

Users join the platform by answering questions about themselves and agreeing to share their information through location checking in or by connecting their social media accounts. Based on data, users are grouped into anonymized advertising groups to which advertisers buy access, enabling users to earn a portion of the revenue from the data sale.

Currently, big social media platforms are experiencing a strong public backlash as consumers demand to keep their data private. In addition, as consumers become increasingly aware of the value of their data, they expect to receive compensation for releasing their information.

As data-savvy consumers argue for more protection, regulations designed to grant that protection are beginning to roll through the United States as well as around the world, catching some social media giants off-guard. State and federal privacy laws such as the California Consumer Privacy Act, which goes into effect this month, are putting control over data back in the hands of the consumer; similar legislature is being adopted in 13 more states as well as across Europe and India. This is increasingly affecting the way that marketers can reach current and potential customers. Thanks to BIGtoken, SRAX is well positioned to capitalize on the national and international regulatory changes aimed at protecting consumer data while opening up monetization opportunities for those consumers who opt into data sharing.

In addition to BIGtoken, SRAX has also developed SRAX IR, a product that uses behavioral data to help public companies identify developments within the supply and demand of their publicly traded stocks. SRAX IR helps stock companies reach potential investors based on current stock buyers’ behavior and trends, monitor shareholders’ behavior, uncover trends from buyers and sellers, analyze activity from market makers and track return on investment from investor relations programs.

Data monetization is a multibillion-dollar market. Global spending on business analytics and big data amounted to $166 billion in 2018 and is projected to reach $260 billion by 2022 (http://ibn.fm/BcMRZ). As consumers take back privacy and data ownership, supported by the regulatory changes worldwide, SRAX is poised to harness the rapid growth of this multibillion-dollar market.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Industry article notes that successful direct-selling companies embrace smart systems that unify necessary tools to drive distributors’ success
• SHRG’s Elepreneurs adopting the interactive, video-based VERB sales-marketing app
• Elevacity D.O.S.E. products designed, formulated around scientifically backed, carefully researched ingredients

Integrating operations and activities into a single platform and fighting health problems through research and education are two key trends for the direct-selling sector moving into a new year, according to a recent article (http://ibn.fm/XZYuc), titled ‘The Top 7 Direct-Selling Trends to Watch for in 2020’. Sharing Services Global Corporation (OTCQB: SHRG), a diversified holdings company in the direct-selling industry, is leading out in these areas, as well as others designed to continue the company’s incredible momentum created in 2019.

“Since the majority of distributors are involved in a direct selling business only part-time and try to fit their side gig into busy schedules, every aspect of their entrepreneurial journey should be as smooth and easy as possible,” the article noted. “That’s why for direct-selling companies, it’s crucial to provide their distributors with tools and resources to ensure they have everything for easily achievable success. . . . Scattered solutions for every small challenge are not an option anymore. Successful direct-selling companies embrace smart systems that unify all the necessary tools to drive distributors’ success. Such systems are customizable to the core and combine training, engagement, genealogy management, payment processing, business development and other tools, ensuring that all the distributors are supported at each step on their way to success.”

On top of the trend, Sharing Services and its growing independent sales force, called Elepreneurs, use the interactive, video-based VERB sales-marketing app platform developed by Verb Technology Company Inc. (http://ibn.fm/lN51c). The innovative app combines world-class sales tools and allows users to track analytics in real time, deliver video messages, facilitate promotions and increase retention, manage social campaigns and much more. VERB is only the latest component of SHRG’s powerful selling strategy, which combines online technological tools and a specialized, seamless selling experience offered by its Elepreneurs.

SHRG’s implementation of VERB isn’t the only leading-edge move the company has made. The company created a wholly owned subsidiary – Elevacity LLC – that is focused on elevating health, wealth and happiness through a patented, powerful product line. Elevacity D.O.S.E. products are designed and formulated around scientifically backed, carefully researched ingredients proven to stimulate the happiness hormones: dopamine, oxytocin, serotonin and endorphins.

In addition to Elevacity, Sharing Services created a second subsidiary – named Elepreneurs LLC after its sales reps – specifically to answer the call of a new era of individuals in the gig economy who are looking for greater flexibility with income opportunities and a path to living happier, healthier and wealthier lives. Elepreneurs meets the needs of a “new era of social media and a widened consumer base that crosses industries and borders. ‘Relationship Marketing,’ or ‘word-of-mouth’ marketing breaks the traditional mold and creates competitiveness and big opportunities in the hands of small businesses across the company’s platform,” the company noted in a news release (http://ibn.fm/J4AQQ). “The company’s successful strategy reaches today’s market and consumers in an extremely cost-effective and more personal and direct approach.”

Since the creation of both Elepreneurs and Elevacity, along with the release of the D.O.S.E. products, Sharing Services has seen consistently impressive growth each quarter. “For the full fiscal year ended April 30, 2019, cash provided by operations was $6.0 million on annual sales of $85.9 million,” the company recently reported (http://ibn.fm/ZQrS9). “In addition, for the six months ended October 31, 2019, cash provided by operations was $12.1 million on sales of $74.3 million, while operating earnings were $3.9 million. As of October 31, 2019, cash and cash equivalents were $12.8 million.”

Sharing Services is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling industry. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. Two of its primary divisions include Elevacity Holdings LLC (a product-sourcing and supply company) and Elepreneurs Holdings LLC (a sales and marketing company based on utilization of independent contractors as the sales force).

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Wonderfilm expects to generate $100 million in revenue by 2021, $20 million in deferred revenue early next year
• Company is backed by four Hollywood producers who produced over $1 billion dollars of hit movie revenue
• 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017
• Entertainment and media industry’s revenue to reach $2.4 trillion globally in 2022

Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), a leading entertainment company, is finding a lucrative market niche amid rising demand for streaming services. The race to capture content streaming consumers is a salient feature of entertainment, and the company has become more attractive to investors than ever before as a new provider of quality content.

Global demand for streaming content is at an unprecedented high. Almost a fifth of respondents in a survey by Colling Media stated they had canceled cable television, and 39% of consumers subscribed to streaming services between June and July 2019 (http://ibn.fm/Nxvac). Roughly 69% of U.S. households now subscribe to streaming video services, up from 55% in 2017. Consumers are willing to spend more on content they want, which is an excellent opportunity for companies like Wonderfilm.

Moreover, total global spending on entertainment and media is expected to rise at a compound annual growth rate (CAGR) of 4.4% over the next five years. The industry’s global revenue will reach $2.4 trillion in 2022 as a result, up from $1.9 trillion in 2017, a PwC report shows (http://ibn.fm/qb0Qk).

As streaming video on demand providers are investing in existing and new content heavily and making efforts to attract major filmmakers, Wonderfilm has an excellent opportunity to jump the bandwagon with around 100 films streaming on Netflix platform. The company differentiates itself by setting up each film as a single-purpose entity packaged for upfront sale, thereby eliminating filmmaking risk (http://ibn.fm/hqSw3).

Wonderfilm’s joint venture Wonderfilm Global, an international company distributing and selling film and TV, is expected to generate substantial revenue as well. The company had relationships with foreign buyers before launching the joint venture and being able to sell to them directly was an important milestone.

The company has lucrative prospects for many reasons. Giants like Google, Disney, Apple and Microsoft are competing with Netflix for streaming service subscribers. Wonderfilm caters to great demand for quality content and retains a continuing annual production slate of $58 million to meet the constant and growing need for content worldwide.

The company has eight green-lit in-development features representing $60 million in production budgets. These include Amityville 1974, in theatres October 2020, and the action film Inside Game with Tyrese Gibson, in theatres sometime in the fall of 2020. The company is also currently developing secured valuable IP rights.

Wonderfilm is backed by four Hollywood producers, who have over $1 billion worth of hit movie revenues under their belts. The company brings several leading industry executives with impressive track records of individual success into a new wider business model. Based on this model, they are capable of quickly financing and flexibly producing fresh slates of film and TV content for U.S. and foreign markets.

Wonderfilm expects $20 million in deferred revenue early this year and has positioned itself to realize $100 million in revenue by 2021. On the stock market, it is undervalued by a factor of 23 with a market cap of $5.2 million. It is a leading publicly traded entertainment company with offices in Los Angeles and Vancouver.

For more information, visit the company’s website at www.Wonderfilm.com

NOTE TO INVESTORS: The latest news and updates relating to WDRFF are available in the company’s newsroom at http://ibn.fm/WDRFF

• MCTC Holdings Inc. (soon to become Cannabis Global Inc.) is a cannabis science innovator working to develop marketable infusion technologies based on the premise of cannabinoid extract efficiency at extremely low quantities
• MCTC recently announced the launch of Project Varin, an effort to develop nanoparticle and nano fiber expressions of ultra-rare tetrahydrocannabivarin (THC-V) and to make those useful biologically at such extremely small levels
• The company also plans to develop the rare cannabinol (CBN) extract by the same means
• MCTC recently announced a new revenue stream through an infused coffee product under its Hemp You Can Feel label

Visionary cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC) is announcing a strategic effort to develop an efficient nanoparticle-based means of using the rare but potentially serviceable tetrahydrocannabivarin (THC-V) extract for purposes such as appetite suppression and obesity reduction.

Since reorganizing its management last year to focus its budding cannabis industry strategy on the science of alcohol replacement, MCTC Holdings has indicated its intentions to patent delivery methods that use minuscule particles of cannabis for a low-quantity but high-efficiency series of products. To that end, the company’s research and development strategy has included plans to delve into the potential of cannabis-based polymeric solid nanoparticles and nanofibers.

The company’s recent announcement states that it has launched Project Varin with the primary goal of developing THC-V delivery methods that significantly improve its bioavailability, using MCTC’s patent-pending technologies to produce THC-V polymeric nanoparticles and nanofibers (http://ibn.fm/WU5EA).

“THC-V is so rare and difficult to obtain, it is currently valued at around $500,000 per kilogram, which is approximately ten times the price of gold,” CEO Arman Tabatabaei stated in the news release. “In order for the marketplace to utilize this potentially beneficial exotic cannabinoid, new delivery systems will need to be developed to allow the amount of THC-V administered to be efficiently utilized by the human body… It is our goal to solve this pressing industry issue. Based on our already completed laboratory accomplishments and our patent-pending technologies, we believe this goal is within our reach.”

Nanoparticles have long been used by the food and medical industries to make products more efficient, turning extremely small substances into a means of quickly delivering their payloads directly to the bloodstream rather than following the dilutive and dilatory digestive tract mechanism commonly employed for swallowed products.

MCTC has been working toward an infused beverage product as a replacement for alcohol, and recently announced that it has developed a cannabinoid-infused clean label coffee that will be rolled out later this month under the company’s Hemp You Can Feel™ brand (http://ibn.fm/SuhJJ). MCTC plans to use its efficiency-promoting patents to harvest the benefits of cannabinoid extracts from very small amounts of the extract while achieving results that are similar or superior to other infusion methods, and to license its technology to other companies on a white label basis.

Under the first stage of development for THC-V, Project Varin is developing nanoparticle and nanofiber expressions of the extract using MCTC’s technology. In March, the second phase of development is expected to begin as the company applies its ongoing cannabinoid glycosides research to making THC-V useful at minimal usage levels.

“Interest in THC-V and Cannabinol (CBN) is quickly growing within the cannabinoid industry, and we believe both will be important topics throughout 2020 and beyond,” Tabatabaei stated. “With the recent availability of nearly 100% pure research quantities of these exotic cannabinoids now hitting the marketplace and the piquing interest, we believe our timing in launching Project Varin is optimal. … We plan to apply what we have learned and our new patent-pending technologies to THC-V and eventually to CBN.”

MCTC has filed five patents on hemp extract technologies and delivery systems.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC

• CIIX CEO said company will employ social media as it markets new CBD products starting March 2020
• CIIX subsidiary CBD Biotech Co. focused on driving growth, building online sales to younger demographics in China
• Goals of CIIX strategy include profitability, expansion of market, maximized impact

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said the company will adopt social media multiplatform techniques to market new CBD products beginning in March 2020. The move is designed to boost online sales to a younger demographic in China through its subsidiary CBD Biotech, explained Wang during a MoneyTV interview with host Donald Baillargeon. In the interview, Wang also outlined the company’s path to profitability in fiscal 2020 and 2021.

“CBD Biotech’s goal in 2020 is to make a profit,” Wang stated in the interview. “That is the key of the stock market. That’s the key for our stock price. That’s the key for our shareholders. CIIX plans to launch a breakthrough CBD product in March. It will debut through its B2B partners through social media, such as TikTok, and target in China a lot of young people.”

One important aspect of the company’s strategy to increase profit is to sell its new CBD product through e-commerce using different social media platforms in 2020. Wang observed that multi-platform social media would play a key role in the company’s marketing to a younger consumer audience of its CBD line. He specifically mentioned using platforms such as TikTok in the campaign, which launched in 2017 and accrued 500 million users in its first two years. Recently hailed as a “must for every small business,” social media marketing gives companies more direct access to their customers, meeting them where they are in a cost-effective way. Social media marketing has also been linked with increased brand recognition (http://ibn.fm/YOANZ), allowing companies to “target and retarget ideal consumers.” CIIX hopes to engage audiences of all ages through social media as it increases traction for its new CBD offerings.

In addition to its anticipated CBD product, CBD Biotech currently markets a line of hemp-infused cosmetics products in China. Wang estimates that cosmetics could deliver profit margins of 10-20 times for the company (http://ibn.fm/G89BP). “That’s quite a big profit,” he noted.

Referencing the high gross margins of CBD cosmetics, Wang said the company is working to bring more of that profitability down to the bottom line through lower costs and a restructuring. Wang explained that CIIX intends to expand its market as it maximizes sales through a split configuration of its B2B and B2C divisions.

The B2C division would focus on marketing and selling to consumers while the B2B division would be responsible for maximizing revenue to wholesalers and through multilevel social media outlets, he explained. The combined aim of the two divisions is to raise sales, cut costs and achieve profitability, he said.

Wang sees subsidiary CBD Biotech company reaching profitability by Q4 2020 fiscal year and continuing into 2021. “I am very positive about CBD in 2020, very excited,” he concluded.

CIIX is a diverse company driven not only by sales of cosmetics, hemp wine and CBD but also educational services. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and educational-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported
• Doctors attribute precision medicine with playing significant role in decline
• POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project

A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://ibn.fm/1d3lE). The 2.2% drop occurred from 2016 to 2017, the most recent year for which complete data is available.

The report notes that the decline in deaths from lung cancer drove the record drop, and that the decline was driven in large part by precision medicine. While lung cancer is still the leading cause of cancer death, deaths from lung cancer have declined by 51% from 1990 to 2017 among men and 26% from 2002 to 2017 among women. In response to the report, doctors at Roswell Park Comprehensive Cancer in Buffalo, New York, attribute precision medicine with playing a significant role in the decline (http://ibn.fm/14kPm).

Roswell Park’s Dr. Carl Morrison described the impact that precision medicine has had on the health industry’s fight against cancer. For example, there are at least 10 to 15 subtypes of lung cancers that doctors can treat now, which patients couldn’t receive treatment for previously. “Ten years ago, you stopped at that diagnosis,” Morrison said in an article. “Today you don’t. No longer can you just use the word lung cancer. You have to clarify what types of lung cancer it is, and then when you know what type of lung cancer it is, you know what specific therapy that you can treat that lung cancer with and that is in essence, precision medicine.”

As precision medicine continues to be embraced by the health community, Predictive Oncology’s database shows potential to fill a critical void: equipping oncological and pharmaceutical industries with tools to help fight ovarian cancer – a notoriously fast-moving and aggressive cancer type. Last year, POAI initiated its Cancer Quest 2020 project, which includes sequencing ovarian cancers and building the largest ovarian cancer multi-omic database in the world. Through this project, the company hopes to provide the pharmaceutical industry critical tools to help speed up the development of new drugs and provide more personalized and effective therapeutic choices.

Predictive Oncology’s subsidiary, Helomics, is playing a key role in the groundbreaking project. Helomics currently has an estimated 150,000 cases on its molecular information platform – 38,000 of which are specific to ovarian cancer. This invaluable scientific asset positions POAI as a leader in providing the critical molecular information needed for more effective patient treatments and new drug discovery in a much timelier manner than others in the precision-medicine space.

As part of the Cancer Quest 2020 project, Predictive Oncology has also signed a collaborative agreement with the University of Pittsburgh Medical Center (UPMC)-Magee Women’s Hospital to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to help oncologists predict clinical outcomes for ovarian cancer patients.

Helomics has begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration and analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer. This disruptive work is designed to lead to continued drops in cancer deaths of all types.

Predictive Oncology began as a joint venture between Skyline Medical, another of POIA’s subsidiaries, and Helomics. The company is ideally positioned to harness the power of artificial intelligence and work with the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Merger with Pura Vida Health seen as mutually beneficial for both players in the CBD health and wellness space
• EMOR’s Pura Vida business plan allows the company to achieve full vertical integration
• The company promises quality control of CBD product offerings, from seed to shelf

Emerald Organic Products Inc. (OTC: EMOR), a diversified cannabidiol (CBD)-focused health sciences company, recently announced the completion of a definitive plan to merge with Pura Vida Health LLC, a health and wellness company focused on using natural ingredients – including the increasingly desired CBD – to help customers achieve optimal health. This mutually beneficial merger is expected to allow Pura Vida to become a flagship brand for Emerald Organic Products and position the former for maximum market penetration, with the help of EMOR’s proven track record in product branding and sales.

“We believe in the all-star team we put together, we have proven experts in cannabis, hemp, CBD,” Pura Vida CEO and Executive Chairman Matt Dill stated in a news release (http://ibn.fm/tfRrQ). “I am talking all phases: planting, farming, extracting, the whole way, fully vertical.” Commenting on how his company will benefit from the alignment with Emerald Organic Products, he noted, “Add a group of professionals with a track record of successful branding of products, hundreds of millions in sales, [it’s] very exciting.”

Pura Vida is focused on bringing products to market that are engineered to help people live their healthiest lives. The company is committed to providing the highest quality products using natural ingredients and third-party testing (http://ibn.fm/j5YKm). Coupling Pura Vida’s insistence on quality with EMOR’s marketing muscle is expected to lend the combined firm an advantageous position in the burgeoning industry.

Based out of New York, Emerald Organics Products plans to market its recently commercialized line of vitamins and supplements both across the nation and in certain foreign countries. Its Pura Vida business plan will allow it to achieve full vertical integration – ensuring absolute quality control, from seed to shelf. The process includes careful monitoring of hemp growth and CBD extraction and following the product through manufacturing and production at its facilities in Oregon and New York, respectively. By overseeing each stage, Emerald Organics Products will be one step closer to its goal of ‘leading the hemp revolution’ (http://ibn.fm/lWjJt).

Creating a symbiotic relationship between the two companies, the merger comes at an opportune time. According to Grand View Research, the global cannabidiol market was valued at $4.6 billion in 2018 and is forecast to experience an impressive CAGR of 22.2% through 2025 (http://ibn.fm/PS3WC). In the health and wellness industry, there is particularly high demand for products infused with CBD due to its healing properties, including its efficacy in treating anxiety, depression and stress; its mitigation of cancer symptoms; and other applications. As government legalization and approval continue to roll through North America, the potential for companies bringing CBD offerings to market is also anticipated to grow.

Emerald Organic Products Inc. is engaged in the development of vitamins and supplements with cannabidiol (CBD) health and wellness products. The hemp-based proprietary Pura Vida CBD products include CBD vitamins, chewable CBD gummies and gummy bears, vaporization CBD liquids, drinks, CBD tinctures, CBD cosmetics and others.

For more information, visit the company’s website at www.Emerald-Organic.com